Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 7/20 | 0.48 |
| ▸ | MLYCD | O95822 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1461093 | 0.89 | EPHX2 (0.56) | GABRA5GRM5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6930962 | 0.88 | KCNH2 (0.49) | GABRA5GRM5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6929928 | 0.87 | CXCR2 (0.53) | GABRA5MLYCDGRM5EPHX2CXCR2 | |
| SCHEMBL6929241 | 0.84 | GRM5 (0.55) | GABRA5MLYCDGRM5EPHX2CXCR2 | |
| SCHEMBL6930268 | 0.83 | SMN1; SMN2 (0.40) | MLYCDGRM5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2158904 | 0.81 | GRM5 (0.68) | GABRA5GRM5EPHX2CXCR2 | |
| SCHEMBL6930489 | 0.81 | MEN1 (0.43) | GABRA5MLYCDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6927902 | 0.80 | MEN1 (0.46) | GABRA5MLYCDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6931376 | 0.80 | GRM5 (0.51) | GABRA5MLYCDGRM5EPHX2CXCR2 | |
| SCHEMBL6930123 | 0.80 | NOX1 (0.52) | GABRA5MLYCDNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-28 | — | — | US | disclosed |
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-28 | — | — | US | disclosed |
| WO-2011035324-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | VANDERBILT UNIVERSITY (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | GRM5, GRIK5, GRM1 | GABRA5 26/4885MLYCD 2094/4885GRM5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.